LYRA THERAPEUTICS announces additional data presentations FROM PHASE 2 LANTERN STUDY at the americal rhinologic society annual meeting
- Saturday, September 10, 2022, 7:04
- Finance
- Add a comment
Significantly more patients with moderate/severe symptoms of chronic rhinosinusitis at baseline improved to mild/no symptoms at week 24 after treatment with LYR-210 (7500μg) compared to control The three cardinal symptoms composite score shown to correlate with the well-established…
About the Author
adminasapcorp has written 42197 stories on this site.